Figure 3. Cumulative Incidences of Colorectal Cancer and Liver Cancer Among Patients Receiving Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) vs Those Receiving Insulins or Metformin During a 15-Year Follow-Up.

Kaplan-Meier survival analysis was used. Each eligible individual was followed up from the index event until the occurrence of the outcomes, death, loss to follow-up, or 15 years after the index event, whichever occurred first.